Table 4.
Cohort | m | Trial | n | Difference in Mean Change (95% CI) | ||
---|---|---|---|---|---|---|
|
|
|
||||
WIHS | 493 | 320c | 200 | 24 (7, 41) | 38 (17, 59) | 46 (23, 70) |
WIHS | 1,012 | A5202d | 322 | 1 (−35, 37) | −19 (−62, 25) | 35 (−45, 115) |
CNICS | 6,158 | 320 | 1,156 | 19 (12, 25) | 18 (9, 26) | 17 (9, 25) |
CNICS | 12,302 | A5202 | 1,857 | 6 (−8, 20) | 7 (−18, 32) | −2 (−31, 28) |
For 320, the outcome was change in CD4 cell count from baseline to week 4. For A5202, the outcome was change in CD4 cell count from baseline to week 48.
T = within trial; S = stratified; ISPW = inverse probability of sampling weighted.
For 320, the treatment contrast was protease inhibitor (X = 1) vs. no protease inhibitor (X = 0).
For A5202, the treatment contrast was abacavir-lamivudine (X = 1) vs. tenofovir disoproxil fumarate-emtricitabine (X = 0) plus efavirenz or ritonavir-boosted atazanavir.